Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

Presence of both ICAS and non-elevated Lp-PLA2 activity may predict better response to dual antiplatelet therapy in prevention of recurrent strokes and combined vascular events for patients with minor stroke or high-risk TIA.

There are significantly more patients with elevated Lp-PLA2 activity in the ICAS group than that in the non-ICAS group (43.8% versus 35.4%, p=0.02). There was significant interaction between Lp-PLA2 activity levels and the two antiplatelet therapy for prevention of stroke recurrences and combined vascular events even after adjustment for confounding factors exclusively for patients with ICAS (p=0.017, 0.017, respectively), but not for those without (p=0.332, 0.674, respectively). Compared with aspirin alone, dual antiplatelet therapy significantly reduced the risk of stroke recurrences and combined vascular events (adjusted hazard ratio=0.33 [0.12-0.89], p=0.028; 0.33 [0.12-0.89], p=0.028, respectively) for patients with both ICAS and non-elevated Lp-PLA2 activity.